

DIN EN ISO 10993-11:2018-09 (E)

Biological evaluation of medical devices - Part 11: Tests for systemic toxicity (ISO 10993-11:2017)

| Contents | Page |
|---|-----------|
| European foreword..... | 4 |
| Endorsement notice..... | 5 |
| Annex ZA (informative) Relationship between this European Standard and the essential requirements of Directive 93/42/EEC [OJ L 169] aimed to be covered..... | 6 |
| Annex ZB (informative) Relationship between this European Standard and the essential requirements of Directive 90/385/EEC [OJ L 189] aimed to be covered..... | 8 |
| Foreword..... | 10 |
| Introduction..... | 11 |
| 1 Scope..... | 12 |
| 2 Normative references..... | 12 |
| 3 Terms and definitions..... | 12 |
| 4 General considerations..... | 14 |
| 4.1 General..... | 14 |
| 4.2 Selection of animal species..... | 14 |
| 4.3 Animal status..... | 14 |
| 4.4 Animal care and husbandry..... | 14 |
| 4.5 Size and number of groups..... | 15 |
| 4.5.1 Size of groups..... | 15 |
| 4.5.2 Number of groups..... | 15 |
| 4.5.3 Treatment controls..... | 15 |
| 4.6 Route of exposure..... | 16 |
| 4.7 Sample preparation..... | 16 |
| 4.8 Dosing..... | 16 |
| 4.8.1 Test sample administration..... | 16 |
| 4.8.2 Dosage volumes..... | 16 |
| 4.8.3 Dosage frequency..... | 17 |
| 4.9 Body weight and food/water consumption..... | 17 |
| 4.10 Clinical observations..... | 17 |
| 4.11 Clinical pathology..... | 17 |
| 4.12 Anatomic pathology..... | 18 |
| 4.13 Study designs..... | 18 |
| 4.14 Quality of investigation..... | 18 |
| 5 Acute systemic toxicity..... | 18 |
| 5.1 General..... | 18 |
| 5.2 Study design..... | 19 |
| 5.2.1 Preparations..... | 19 |
| 5.2.2 Experimental animals..... | 19 |
| 5.2.3 Test conditions..... | 19 |
| 5.2.4 Body weights..... | 20 |
| 5.2.5 Clinical observations..... | 20 |
| 5.2.6 Pathology..... | 20 |
| 5.3 Evaluation criteria..... | 21 |
| 5.3.1 General..... | 21 |
| 5.3.2 Evaluation of results..... | 21 |
| 5.4 Final report..... | 21 |

| | | |
|----------|---|-----------|
| 6 | Repeated exposure systemic toxicity (subacute, subchronic and chronic systemic toxicity) | 23 |
| 6.1 | General | 23 |
| 6.2 | Study design | 23 |
| | 6.2.1 Preparations | 23 |
| | 6.2.2 Experimental animals | 23 |
| | 6.2.3 Test conditions | 24 |
| | 6.2.4 Body weights | 24 |
| | 6.2.5 Clinical observations | 24 |
| | 6.2.6 Pathology | 24 |
| 6.3 | Evaluation criteria | 25 |
| | 6.3.1 General | 25 |
| | 6.3.2 Evaluation of results | 25 |
| 6.4 | Final report | 26 |
| | Annex A (informative) Routes of administration | 27 |
| | Annex B (informative) Dosage volumes | 29 |
| | Annex C (informative) Common clinical signs and observations | 30 |
| | Annex D (informative) Suggested haematology, clinical chemistry and urinalysis measurements | 31 |
| | Annex E (informative) Suggested organ list for histopathological evaluation | 33 |
| | Annex F (informative) Organ list for limited histopathology for medical devices subjected to systemic toxicity testing | 35 |
| | Annex G (informative) Information on material-mediated pyrogens | 36 |
| | Annex H (informative) Subchronic rat — Dual routes of parenteral administration | 37 |
| | Bibliography | 39 |